Larimar Therapeutics, Inc.
7 clinical trials · Sponsor
◉ Watch Larimar Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia (NCT06681766) | Larimar Therapeutics, Inc. | 2024-12-06 |
| An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia (NCT06447025) | Larimar Therapeutics, Inc. | 2024-01-25 |
| A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia (NCT05579691) | Larimar Therapeutics, Inc. | 2022-09-21 |
| Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers (NCT05028764) | Larimar Therapeutics, Inc. | 2021-08-04 |
| Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia (NCT04519567) | Larimar Therapeutics, Inc. | 2020-07-31 |
| A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia (NCT04255680) | Larimar Therapeutics, Inc. | 2020-01-14 |
| Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia (NCT04176991) | Larimar Therapeutics, Inc. | 2019-12-11 |
Track Larimar Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.